Tivic Health Systems Inc. will attend a follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) on March 10, 2026, to continue discussions on clinical data and potential U.S. government funding and stockpiling of its TLR5 agonist Entolimod for Acute Radiation Syndrome. Event-related link: https://www.accessnewswire.com/
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202602180915ACCESSWRNAPR_____1138397) on February 18, 2026, and is solely responsible for the information contained therein.